13-110622240-G-C
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001242882.2(NAXD):āc.71G>Cā(p.Arg24Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000252 in 1,613,462 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_001242882.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NAXD | NM_001242882.2 | c.71G>C | p.Arg24Pro | missense_variant | 2/10 | ENST00000680254.1 | NP_001229811.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NAXD | ENST00000680254.1 | c.71G>C | p.Arg24Pro | missense_variant | 2/10 | NM_001242882.2 | ENSP00000505619.1 |
Frequencies
GnomAD3 genomes AF: 0.000197 AC: 30AN: 152070Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000195 AC: 49AN: 250694Hom.: 0 AF XY: 0.000184 AC XY: 25AN XY: 135564
GnomAD4 exome AF: 0.000257 AC: 376AN: 1461274Hom.: 1 Cov.: 31 AF XY: 0.000252 AC XY: 183AN XY: 726918
GnomAD4 genome AF: 0.000197 AC: 30AN: 152188Hom.: 0 Cov.: 33 AF XY: 0.000202 AC XY: 15AN XY: 74416
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 17, 2021 | The c.125G>C (p.R42P) alteration is located in exon 2 (coding exon 2) of the NAXD gene. This alteration results from a G to C substitution at nucleotide position 125, causing the arginine (R) at amino acid position 42 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2021 | This sequence change replaces arginine with proline at codon 42 of the NAXD protein (p.Arg42Pro). The arginine residue is weakly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs149247530, ExAC 0.03%). This variant has not been reported in the literature in individuals affected with NAXD-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at